Want to see ALLR full AI Analyst Report?
Top Page
Allarity Therapeutics
(NASDAQ:ALLR)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▲(11.94% Upside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by very weak financial performance (minimal revenue, sizable ongoing losses and cash burn) and a materially higher leverage profile (debt far exceeding equity). Technical indicators are relatively neutral with mild positive momentum, but valuation remains difficult to support with a negative P/E and no dividend yield.
Positive Factors
U.S. Patent Protection
The U.S. patent strengthens Allarity’s intellectual-property position around stenoparib patient selection. Long exclusivity could support future partnering, regulatory differentiation, and commercial opportunities if the therapy and diagnostic achieve approval.
Negative Factors
Minimal Revenue Base
The company lacks meaningful recurring commercial revenue and has no demonstrated growth trend. As a pre-commercial biotech, it remains dependent on financing, collaborations, or future product success to support research and corporate operations.
Read all positive and negative factors
Positive Factors
Negative Factors
U.S. Patent Protection
The U.S. patent strengthens Allarity’s intellectual-property position around stenoparib patient selection. Long exclusivity could support future partnering, regulatory differentiation, and commercial opportunities if the therapy and diagnostic achieve approval.
Read all positive factors
Allarity Therapeutics (ALLR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$21.32M
Dividend YieldN/A
Average Volume (3M)146.33K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue GrowthN/A
EPS Growth91.38%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.78
Shares Outstanding15,910,724
10 Day Avg. Volume114,973
30 Day Avg. Volume146,334
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.58
Price to Sales (P/S)48.53
P/FCF Ratio-1.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.25Price Target Upside664.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.92
Revenue Forecast (FY)N/A
Allarity Therapeutics Business Overview & Revenue Model
Company Description
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which ...
How the Company Makes Money
Allarity Therapeutics is a clinical-stage biotech company and, as such, it typically does not generate meaningful recurring revenue from commercial product sales because it does not have widely marketed, approved therapies. Based on publicly avail...
Allarity Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 345.00K | 320.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 371.00K | 320.00K | 0.00 | -37.00K | -120.00K | -106.00K |
| EBITDA | -11.09M | -11.05M | -24.23M | -11.28M | -17.30M | -25.77M |
| Net Income | -12.33M | -11.23M | -24.52M | -11.90M | -16.06M | -26.65M |
Balance Sheet | ||||||
| Total Assets | 32.12M | 18.26M | 22.65M | 11.86M | 14.54M | 49.63M |
| Cash, Cash Equivalents and Short-Term Investments | 16.98M | 14.69M | 19.53M | 166.00K | 2.03M | 19.91M |
| Total Debt | 22.29M | 1.40M | 1.35M | 1.30M | 3.73M | 1.09M |
| Total Liabilities | 28.58M | 8.43M | 10.84M | 14.61M | 12.65M | 30.85M |
| Stockholders Equity | 3.54M | 9.83M | 11.81M | -2.75M | 1.89M | 18.78M |
Cash Flow | ||||||
| Free Cash Flow | -13.78M | -14.83M | -17.65M | -12.74M | -16.84M | -15.05M |
| Operating Cash Flow | -13.71M | -14.82M | -17.35M | -12.74M | -16.82M | -15.05M |
| Investing Cash Flow | -64.00K | -8.00K | -298.00K | 0.00 | 791.00K | 1.00M |
| Financing Cash Flow | 21.81M | 10.65M | 36.79M | 10.99M | -1.31M | 33.82M |
Allarity Therapeutics Risk Analysis
Allarity Therapeutics disclosed 82 risk factors in its most recent earnings report. Allarity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allarity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $224.23M | -0.67 | -223.19% | ― | -42.74% | 20.66% | |
46 Neutral | $21.32M | -1.77 | -109.94% | ― | ― | 91.38% | |
45 Neutral | $3.22M | -0.11 | 805.67% | ― | -62.17% | 85.37% | |
43 Neutral | $16.31M | -1.11 | -101.90% | ― | -90.65% | 26.48% |
* Healthcare Sector Average
ALLR
Allarity Therapeutics
1.38
-0.16
-10.39%
LSTA
Lisata Therapeutics
1.82
-0.50
-21.55%
CRIS
Curis
1.50
-31.90
-95.51%
LGVN
Longeveron
6.80
-1.48
-17.88%
Allarity Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesProduct-Related AnnouncementsRegulatory Filings and ComplianceShareholder Meetings
Allarity Wins Key U.S. Patent for Stenoparib Diagnostic
Positive
Jul 1, 2026
On June 26, 2026, Allarity Therapeutics, Inc. held its annual meeting of stockholders, with 54.10% of outstanding common shares represented, establishing a quorum for seven corporate proposals. Shareholders elected Jesper Hoiland as director throu...
Executive/Board Changes
Allarity Therapeutics Updates CEO Management and Compensation Agreement
Neutral
Jun 2, 2026
Effective June 1, 2026, Allarity Therapeutics entered into an Amended and Restated Management Services Agreement with Ljungaskog Consulting AB, which replaces the original June 1, 2024 pact governing CEO Thomas H. Jensen’s services. The revi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.